SHW
42
9
AZO
53
4
AN
41
-2
UNH
49
3
FTI
61
-2
BMY
43
3
AMT
30
9
LUV
33
4
ZTS
27
4
TJX
53
3
LRCX
49
-6
HOG
45
-3
PCG
81
3
MKC
48
7
KR
56
3
HCP
31
-5
IBM
50
3
NDAQ
32
4
LH
35
3
HON
52
2
SHW
42
9
AZO
53
4
AN
41
-2
UNH
49
3
FTI
61
-2
BMY
43
3
AMT
30
9
LUV
33
4
ZTS
27
4
TJX
53
3
LRCX
49
-6
HOG
45
-3
PCG
81
3
MKC
48
7
KR
56
3
HCP
31
-5
IBM
50
3
NDAQ
32
4
LH
35
3
HON
52
2
Financhill
Back

BioXcel Therapeutics 10K Form

Sell
33

BTAI
BioXcel Therapeutics

Last Price:
18.31
Seasonality Move:
46.06%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BTAI News And Ratings

See the #1 stock for the next 7 days that we like better than BTAI

BTAI Financial Statistics

Sales & Book Value

Annual Sales: $380K
Cash Flow: $-38.64M
Price / Cash Flow: 0
Annual Sales: $2.73
Price / Book: 6.92

Profitability

EPS (TTM): -5.91000
Net Income (TTM): $-165.76M
Gross Margin: $360K
Return on Equity: 0%
Return on Assets: 0%

BioXcel Therapeutics Earnings Forecast

Key BioXcel Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 2 years for BTAI is 94.74%.
  • The Selling, General & Administrative Expenses for BTAI have been equal to 18,094.74% of Gross Profit Margin.
  • The Research & Development expenses have been 24,010.53% of Revenue.
  • The Interest Expense is -4.95% of Operating Income.
  • The Net Earning history of BTAI is -43,621.05% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 0 years.

BioXcel Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: BTAI
CUSIP: 09075P
Website: bioxceltherapeutics.com

Debt

Debt-to-Equity Ratio: 1.21
Current Ratio: 6.17
Quick Ratio: 5.9

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BTAI Technical Analysis vs Fundamental Analysis

Sell
33
BioXcel Therapeutics (BTAI) is a Sell

Is BioXcel Therapeutics a Buy or a Sell?